Cytokine receptor and JAK/STAT pathway mutations in acute myeloid leukemia: Prevalence and clinical impact
Cancer · 2026
DOI: 10.1002/cncr.70465 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer, 2026. Verfasst von Moath Albliwi und 22 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Cleveland Clinic, Cleveland, Ohio, USA. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, STAT Transcription Factors, Receptors, Cytokine, Janus Kinases. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
Mutations in cytokine receptor and JAK/STAT; Cy‐JAK/STAT) signaling genes drive myeloproliferative neoplasms (MPNs) but remain incompletely characterized in acute myeloid leukemia (AML). The authors evaluated the prevalence, clinical presentation, and prognostic significance of Cy‐JAK/STAT pathway mutations in patients with AML and compared outcomes across disease ontogeny.
Methods
In total, 971 adults with newly diagnosed AML who were treated at the Cleveland Clinic between January 2015 and September 2023 were retrospectively analyzed. Baseline next‐generation sequencing was queried for eight Cy‐JAK/STAT pathway genes: CALR , JAK1 , JAK2 , JAK3 , MPL , SH2B3 , STAT3 , and STAT5B . Outcomes included composite‐complete remission (complete remission or complete remission with incomplete hematologic recovery), event‐free survival, and overall survival. In a prespecified subgroup of patients who had baseline molecular testing results available ( n = 621), those who had blast‐phase MPN ( n = 68), de novo AML with JAK2 / CALR / MPL mutations ( n = 23), and de novo AML without Cy‐JAK/STAT mutations ( n = 530) were compared.
Results
Mutation frequencies for the eight genes were as follows: JAK2, 43 of 625 patients (6.9%); CALR, nine of 623 (1.4%); SH2B3, eight of 392 (2.0%); JAK3, five of 439 (1.1%); MPL, one of 639 (0.2%); and STAT5B, one of 390 (0.3%); no JAK1 or STAT3 mutations were detected. The median follow‐up among survivors was 40.9 months, and the median overall survival was 12 months. JAK2‐mutated AML was associated with higher cardiovascular comorbidity, lower complete remission/complete remission with incomplete hematologic recovery rates (32% vs. 54%), and inferior overall survival ( p < .05), but not on multivariable analysis. In subgroup analyses, patients who had blast‐phase MPN had the lowest response rate (13%) and the poorest survival; whereas patients who had de novo AML with JAK2 , CALR , or MPL mutations had intermediate outcomes versus those who had mutation‐negative, de novo AML (41% vs. 57% complete remission).
Conclusions
Cy‐JAK/STAT pathway mutations are uncommon in AML, but each mutation has distinct biologic and clinical characteristics. The worse survival observed in patients with JAK2 ‐mutated AML largely appeared to be driven by the co‐occurrence of high‐risk characteristics. Blast‐phase MPN was associated with a dismal prognosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, Cleveland Clinic, Cleveland, Ohio, USA.
- Department of Quantitative Health Sciences, Cleveland Clinic Research, Cleveland, Ohio, USA.
- Department of Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio, USA.
- Department of Pathology and Laboratory Medicine, Cleveland Clinic Diagnostics Institute, Cleveland, Ohio, USA.
- Department of Cancer Sciences and Center for Immunotherapy and Precision Immuno-Oncology, Cleveland Clinic, Cleveland, Ohio, USA.
ORCID-Profile: Moath Albliwi, Akriti G Jain, Moaath K Mustafa Ali
Zitieren
APA
Albliwi, M., Nurse, D. P., Zabor, E. C., Hanna, J., El-Asmar, J., Bawwab, A., Abuamsha, H., Abu-Farsakh, Y., Batah, H., Rauf, A., Nakitandwe, J., Bosler, D. S., Parthasarathy, P. B., Alban, T., Jain, A. G., Molina, J. C., Balderman, S., Singh, A., Gerds, A. T., …, & Mustafa Ali, M. K. (2026). Cytokine receptor and JAK/STAT pathway mutations in acute myeloid leukemia: Prevalence and clinical impact. Cancer. https://doi.org/10.1002/cncr.70465
Vancouver
Albliwi M, Nurse DP, Zabor EC, Hanna J, El-Asmar J, Bawwab A, et al. Cytokine receptor and JAK/STAT pathway mutations in acute myeloid leukemia: Prevalence and clinical impact. Cancer. 2026. doi:10.1002/cncr.70465
BibTeX
@article{Albliwi2026,
author = {Albliwi, Moath and Nurse, Daniel P and Zabor, Emily C and Hanna, John and El-Asmar, Jessica and Bawwab, Ameed and Abuamsha, Hasan and Abu-Farsakh, Yomna and Batah, Heya and Rauf, Asad and Nakitandwe, Joy and Bosler, David S and Parthasarathy, Prerana Bangalore and Alban, Tyler and Jain, Akriti G and Molina, John C and Balderman, Sophia and Singh, Abhay and Gerds, Aaron T and Mukherjee, Sudipto and Advani, Anjali S and Carraway, Hetty E and Mustafa Ali, Moaath K},
title = {Cytokine receptor and JAK/STAT pathway mutations in acute myeloid leukemia: Prevalence and clinical impact},
journal = {Cancer},
year = {2026},
doi = {10.1002/cncr.70465}
}
EUVIMED